A long-acting injectable is a medication formulated to be given by shot that releases its active ingredient slowly over weeks or months so a patient needs fewer doses. For investors, these products can change a drug’s market value by improving patient convenience and adherence, extending patent life or pricing opportunities, and requiring different manufacturing and regulatory steps compared with daily pills — much like swapping many small payments for a single, larger subscription.
subcutaneousmedical
Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.
marketing authorization applicationregulatory
A marketing authorization application is a formal request submitted to a government regulator asking permission to sell a prescription medicine or medical product in a country or region. Think of it like asking for a business license after showing evidence the product is safe and works; investors care because approval determines whether the product can generate sales, how soon revenue starts, and how much regulatory risk and uncertainty remains.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
MONTPELLIER, France--(BUSINESS WIRE)--
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY®U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year.Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously.
According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers added per month.
Medincell receives mid- to high-single-digit royalties on UZEDY® net sales and is eligible for up to $105 million in commercial milestone payments, subject to the achievement of annual sales thresholds.
UZEDY® is a subcutaneous risperidone LAI (Long-Acting Injectable) approved in the U.S. for schizophrenia (one- and two-month dosing) and Bipolar I Disorder (one-month dosing).
Olanzapine LAI
FDA action on Teva’s once-monthly olanzapine LAI is anticipated in Q4 2026. Teva is preparing for launch, pending regulatory approval.
In Europe, the Marketing Authorization Application was accepted in Q2 2026.
UZEDY® is a trademark of Teva Pharmaceuticals. Medincell’s BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.
1 IQVIA is a global healthcare company specializing in data analytics, clinical research, and technology solutions for the pharmaceutical industry and healthcare stakeholders.
